The intensified interest in LAG-3 combination strategies might be due to the persuasive results of the global, randomized, phase 2–3 study (RELATIVITY-047) in melanoma patients that combined the application of relatlimab (anti-LAG-3) and nivolumab (anti-PD-1). Here, PDCD1 is linked to melanoma.